394. Consistency of AZD7442 (Cilgavimab/Tixagevimab) Pharmacokinetics Across Prophylaxis and Treatment and Adult and Pediatric Participants: Application of Population Pharmacokinetics to Enable Rapid Decision-Making During the COVID-19 Pandemic

BACKGROUND: AZD7442 is a combination of two half-life extended monoclonal antibodies, tixagevimab and cilgavimab. A population pharmacokinetic (popPK) model for AZD7442 included interim data from phase 3 trials in pre-exposure prophylaxis (PreP; PROVENT), post-exposure prophylaxis (STORMCHASER), and...

Descripción completa

Detalles Bibliográficos
Autores principales: Clegg, Lindsay E, Stepanov, Oleg, Schmidt, Henning, Reddy, Ventakesh Pilla, Tang, Weifeng, Gibbs, Michael, Sedani, Sangeeta, Tuillio, Antonella Nadia, Sadow, Sam, Martinez-Alier, Nuria, Cohen, Taylor, Faust, Saul N, Esser, Mark T, Någård, Mats
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679289/
http://dx.doi.org/10.1093/ofid/ofad500.464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679289/
http://dx.doi.org/10.1093/ofid/ofad500.464

Ejemplares similares